BioCrine
  • Home
  • About Us
    • Company and People
    • Board of Directors
    • Management
    • Partners
  • Research Programs
    • Pipeline overview
    • Diabetes as a disease
    • Biocrine drug discovery strategy
    • Serum factor apoCIII
    • Somatostatin receptors
    • Insulin receptor isoforms
    • Calcium channels
    • Imidazolines
    • IP7
  • InSight Technology
    • What is it?
    • How does it work?
    • Where can it be used?
  • News
  • Contact

Research programs

With the goal to find treatment for diabetes, a disease that affects millions of people around the globe, Biocrine aims to commercialize  six patented research programs:
■     Serum factor ApoCIII
■     Somatostatin receptors
■     Insulin receptor isoforms
■     Calcium channels
■     Imidazolines
■     IP7

More on Research programs…

The InSight Technology

The InSight Technology offers a unique opportunity to study molecular processes within a living cell. Following a transplantation of a cell cluster into an eye, any cellular activity can be observed real time with a specifically designed microscope system.

More on InSight Technology…

NEWS

  • Professor Berggren’s distinctions 2012
    Professor Berggren’s distinctions 2012 January 3, 2013
  • Autonomic innervation of beta-cells in InSight
    Autonomic innervation of beta-cells in InSight December 11, 2012
  • Glucagone regulates its own synthesis
    Glucagone regulates its own synthesis December 4, 2012

Biocrine AB

Sveavägen 166, Box 3073

169 03 Solna, Sweden

Contact Us

info at biocrine.se

www.biocrine.com

Copyright © 2012 Biocrine AB. All Rights Reserved